Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 2/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30338608 | 1.00 | GPR119 (0.43) | GPR119CHRM2CHRM1CHRM3USP30 | |
| SCHEMBL25816524 | 0.84 | KMT2A (0.35) | GPR119CHRM2CHRM1CHRM3USP30 | |
| SCHEMBL30338728 | 0.84 | GPR119 (0.33) | GPR119KDM4D | |
| SCHEMBL25816465 | 0.83 | CHRM2 (0.33) | GPR119CHRM2CHRM1CHRM3USP30 | |
| SCHEMBL30338783 | 0.83 | RIPK1 (0.44) | GPR119USP30 | |
| SCHEMBL25816709 | 0.83 | RIPK1 (0.44) | GPR119USP30 | |
| SCHEMBL30338715 | 0.81 | GPR119 (0.32) | GPR119CHRM2CHRM1CHRM3USP30 | |
| SCHEMBL25816719 | 0.81 | GPR119 (0.32) | GPR119CHRM2CHRM1CHRM3USP30 | |
| SCHEMBL30547544 | 0.80 | GPR119 (0.46) | GPR119USP30FAAHKDM4D | |
| SCHEMBL25816509 | 0.80 | GPR119 (0.46) | GPR119USP30FAAHKDM4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116547281-A | Isoxazolidines as RIPK1 inhibitors and uses thereof | 赛诺菲 | 2023-08-04 | — | — | CN | disclosed |
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK4, RIPK2 | GPR119 420/4885CHRM2 4370/4885CHRM1 3460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.